DelveInsight’s, “Postoperative Pain Pipeline Insight, 2023,” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Postoperative Pain pipeline landscape. It covers the Postoperative Pain pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Postoperative Pain Pipeline Report

• DelveInsight’s Postoperative Pain pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Postoperative Pain treatment.
• The leading companies working in the Postoperative Pain market include Concentric Analgesics, Oculis Pharma, Vivozon Pharmaceutical Inc., Haisco Pharmaceutical Group, Jiangsu HengRui Medicine Co., Ltd., Nevakar, Inc., Flexion Therapeutics, LipoCure, SiteOne Therapeutics, Allay Therapeutics, Bexson Biomedical, InSitu Biologics, and others.
• Promising Postoperative Pain Pipeline Therapies in the various stages of development include SABER-Bupivacaine Treatment 1a, Bupivacaine HCl Treatment 1c, Tapentadol IR, Oxycodone IR, Morphine, Tapentadol HCl, Oxycodone, VVZ-149 Injections, Hydromorphone, MDT-10013, and others.
• On August 2023, Paion UK Ltd announced a study of Phase 3 Clinical Trials for Morphine 6-glucuronide. To compare the incidence and severity of nausea in the study treatment groups, during the 18-hour period starting 6 hours after titration to pain relief; following confirmation of the assumption of non-inferiority between the two groups of pain relief over the 24 hour post-operative period. Pain relief and nausea will be determined by measuring the areas under the curves of pain intensity and nausea verbal rating scale scores.
• On August 2023, Laboratorios Liomont announced a study of Phase 2 Clinical Trials for etoricoxib-tramadol, Naproxen, and Tramadol. The goal of the present phase IIb clinical trial was to compare the safety and efficacy of the fixed-dose combination etoricoxib-tramadol 120mg/100mg tablet (once a day, for three days) versus naproxen 220mg tablet plus tramadol 50 mg capsule in patients with acute postoperative pain after impacted third molar extraction.

 

Request a sample and discover the recent advances in Postoperative Pain Treatment Drugs @ Postoperative Pain Pipeline Report

 

The Postoperative Pain pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Postoperative Pain drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Bladder Cancer clinical trial landscape.

 

Postoperative Pain Overview

Postoperative or Postsurgical pain is defined as pain lasting more than 3 to 6 months after surgery. The pain differs in quality and location from pain experienced prior to surgery, and is usually associated with iatrogenic neuropathic pain caused by surgical injury to a major peripheral nerve.

 

Find out more about Postoperative Pain Treatment Drugs @ Drugs for Postoperative Pain Treatment

 

Postoperative Pain Emerging Drugs Profile

• VVZ-149: Vivozon Pharmaceutical Inc.
• CA-008: Concentric Analgesics

 

Postoperative Pain Pipeline Therapeutics Assessment

The Bladder Cancer pipeline report proffers an integral view of the Bladder Cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Postoperative Pain Pipeline Therapies @ Postoperative Pain Clinical Trials Assessment

 

Scope of the Postoperative Pain Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Postoperative Pain Companies- Concentric Analgesics, Oculis Pharma, Vivozon Pharmaceutical Inc., Haisco Pharmaceutical Group, Jiangsu HengRui Medicine Co., Ltd., Nevakar, Inc., Flexion Therapeutics, LipoCure, SiteOne Therapeutics, Allay Therapeutics, Bexson Biomedical, InSitu Biologics, and others.
• Postoperative Pain Pipeline Therapies- SABER-Bupivacaine Treatment 1a, Bupivacaine HCl Treatment 1c, Tapentadol IR, Oxycodone IR, Morphine, Tapentadol HCl, Oxycodone, VVZ-149 Injections, Hydromorphone, MDT-10013, and others.

 

Dive deep into rich insights for new drugs for Postoperative Pain Treatment, Visit @ Postoperative Pain Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Postoperative Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Postoperative Pain– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. VVZ-149: Vivozon Pharmaceutical Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CA-008: Concentric Analgesics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. FX 301: Flexion Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Postoperative Pain Key Companies
18. Postoperative Pain Key Products
19. Postoperative Pain – Unmet Needs
20. Postoperative Pain – Market Drivers and Barriers
21. Postoperative Pain – Future Perspectives and Conclusion
22. Postoperative Pain Analyst Views
23. Postoperative Pain Key Companies
24. Appendix

 

For further information on the Postoperative Pain Pipeline therapeutics, reach out to Postoperative Pain Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting